Disease · MONDO_0011934

dermatofibrosarcoma protuberans

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. dermatofibrosarcoma protuberans. Diseases, record MONDO_0011934. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0011934

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: dermatofibrosarcoma protuberans; Open Targets
Open Targets ID: MONDO_0011934; Open Targets
Other names: DFSP, dermatofibrosarcoma; Open Targets
Disease Ontology: DOID:3507; Disease Ontology
MeSH: D018223; MeSH
NCI Thesaurus: C4683; NCI Thesaurus
Orphanet: ORPHA:31112; Orphanet
Highest stage of its drugs: Approval, for 1 of its 3 drugs, from EMA Human Drugs; Open Targets

Drugs3

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IMATINIB	CHEMBL941	Small molecule	Approval	EMA Human Drugs	10	3	3	Drugs and targets
IMATINIB MESYLATE	CHEMBL1642	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PAZOPANIB	CHEMBL477772	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets13

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KIT	Mast/stem cell growth factor receptor Kit	3	Stem cell growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	3	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/5159	Drugs and targets
ABL1	Bcr/Abl fusion protein	2	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Approval	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	2	Bcr/Abl fusion protein inhibitor	Approval	https://conductscience.org/library/genes/613	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	1	Macrophage colony stimulating factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1436	Drugs and targets
FGFR1	Fibroblast growth factor receptor 1	1	Fibroblast growth factor receptor 1 inhibitor	Phase 2	https://conductscience.org/library/genes/2260	Drugs and targets
FGFR3	Fibroblast growth factor receptor 3	1	Fibroblast growth factor receptor 3 inhibitor	Phase 2	https://conductscience.org/library/genes/2261	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
ITK	Tyrosine-protein kinase ITK/TSK	1	Tyrosine-protein kinase ITK/TSK inhibitor	Phase 2	https://conductscience.org/library/genes/3702	Drugs and targets

1 to 10 of 13

See all 13 targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00243191	Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans	Phase 2	18	2012-03-29	Dermatofibrosarcoma Protuberans	IMATINIB	Its record names the disease	ClinicalTrials.gov
NCT00084630	Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans	Phase 2	40		Adult Fibrosarcoma, Dermatofibrosarcoma Protuberans, Recurrent Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma	IMATINIB	Its record names the disease	ClinicalTrials.gov
NCT00171912	Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes	Phase 2	38		Hypereosinophilic Syndrome, Systemic Mastocytosis, Chronic Myelomonocytic Leukemia, Dermatofibrosarcoma	IMATINIB	Its record names the disease	ClinicalTrials.gov
NCT00122473	Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	Phase 1/2	30		Dermatofibrosarcoma	IMATINIB MESYLATE	Its record names the disease	ClinicalTrials.gov
NCT01059656	Phase II Pazopanib Study in Advanced Dermatofibrosarcomas	Phase 2	23		Dermatofibrosarcomas of DARIER FERRAND(DFSP)	PAZOPANIB	Its record names the disease	ClinicalTrials.gov
NCT00085475	Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma	Phase 2	17		Sarcoma	IMATINIB MESYLATE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
32956651	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0011934

GET https://conductscience.org/api/diseases/v1/MONDO_0011934/drugs

API reference For AI assistants